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Abstract 
 
Tuberculosis is one of the deadliest communicable diseases in the world, and 
consequently remains one of the biggest global healthcare challenges.  Tuberculosis is 
treatable and curable.  However, within many low resource settings, underdeveloped medical 
infrastructure limits the effectiveness and accuracy of existing diagnostics.  These limitations 
severely impede the timely diagnosis of the disease, and thus contribute to the disease 
spreading, developing drug resistance, and killing more individuals.  There is an urgent need 
for an inexpensive, portable, rapid, easy-to-use point of care diagnostic that can function 
outside of the laboratory at the community level.  Currently, there is a wide range of 
available tuberculosis diagnostics ranging from sputum smear microscopy to nucleic acid 
amplification tests.  Yet, none have met every standard of the ideal point of care diagnostic.  
Since the World Health Organization’s endorsement of Xpert MTB/RIF in 2010, there has 
been a resurgence of interest in point of care diagnostic development.  This investigation 
reviewed diagnostic development projects funded by the National Institutes of Health in 2008 
and 2014 in order to examine the technologies being developed, how researchers in industrial 
and academic sectors are addressing this problem, and what challenges still need to be 
overcome.  More projects in 2014 were expected to rely on sample types other than sputum 
and be funded than those in 2008. The results of this investigation confirm this hypothesis, 
and that the development of a point of care device is a multi-faceted challenge with 
numerous underlying issues that need to be addressed before such a device can be 
successfully implemented. 
 
Introduction 
 
Tuberculosis is one of the deadliest communicable diseases, afflicting 9.0 million and 
killing 1.5 million people in 2013 alone (WHO, 2014).  While the disease is treatable and 
curable, it is difficult to diagnose at the point of care in low-resource settings (e.g. Central 
Africa and Southeast Asia) (Davies, 2003).  There are several factors that hinder the 
development of a tuberculosis point of care diagnostic, including the challenge of working 
with sputum, the limitations imposed by low-resource settings, and the cost of technology 
(Wang et al., 2013).  This investigation examines what progress academic and industrial 
sectors have made in the development of a tuberculosis diagnostic.  This was achieved by 
reviewing diagnostic development projects from the years 2008 and 2014 that were funded 
by the National Institutes of Health.  The following sections will provide an overview of 
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tuberculosis, biotechnologies, existing tuberculosis diagnostics, needs assessment, the 
National Institutes of Health, and the predicted outcomes of this investigation.  
I. Biology of Tuberculosis 
Tuberculosis is caused by a bacterium called Mycobacterium tuberculosis.  This 
bacterium is gram positive and possesses cell wall components, such as a high concentration 
of lipids and mycolic acids, that enhance its longevity and ability to trigger inflammatory 
responses from its host (Cole et al., 1998).  M. tuberculosis is an obligate aerobe and is 
commonly found in the lungs, however, complications in extrapulmonary organs may arise 
(WHO, 2014).   
The bacterium spreads to the respiratory tract when people are exposed to droplets 
from infected individuals.  These airborne droplets can be easily spread through coughing 
and sneezing, making the disease highly contagious (Silva Miranda et al., 2012).  The host’s 
immune system detects and fights off the bacteria within these droplets with alveolar 
macrophages, type II pneumocytes, and polymorphonuclear neutrophils (Silva Miranda et al., 
2012).  Alveolar macrophages serve as the first-line of defense against respiratory pathogens 
via phagocytosis and intracellular processes, including the release of cytokines (Rubins, 
2003).  Type II pneumocytes modify the inflammatory response and synthesize alveolar 
surfactant, which reduces surface tension and prevents alveolar collapse (Zhao et al., 2010). 
Polymorphonuclear neutrophils are the most abundant blood leukocytes that serve as the 
first-line of defense against infection and inflammation (Carlo et al., 2001).  These cells, 
along with multinucleated giant cells and T lymphocytes, prevent the disease from spreading 
by forming a granuloma, a structure that contains the infection (Silva Miranda et al., 2012).  
The granuloma is the hallmark signature of tuberculosis infection.  In addition to preventing 
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the disease from spreading, the granuloma can also serve as a niche in which Mycobacterium 
tuberculosis can remain dormant in (Silva Miranda et al., 2012). 
There are two distinct forms of tuberculosis, latent and active.  Latent tuberculosis 
occurs when individuals are infected with the bacterium but do not show symptoms because 
the immune system prevents bacterial proliferation (Silva Miranda et al., 2012).  When the 
immune system is compromised, for instance, by HIV infection, tuberculosis may develop 
into an active disease.  However, the bacteria can successfully infect an individual for 
decades without causing disease (Silva Miranda et al., 2012).  About ten percent of 
individuals with latent tuberculosis will develop active tuberculosis (Fauci, 2008).  Patients 
with latent tuberculosis will test positive for the disease, however, they often do not seek 
treatment in a timely manner due to latent infection not presenting with any symptoms 
(McNerney and Daley, 2011).  Symptoms of tuberculosis include coughing up sputum and 
blood, coughing for three or more weeks, night sweats, fatigue, fever, chest pains, loss of 
appetite, pleurisy, and weight loss (CDC, 2014). 
Latent tuberculosis is typically diagnosed with a Mantoux tuberculin skin test 
whereas active tuberculosis is typically diagnosed by microscopically examining sputum (a 
combination of saliva and mucous obtained from the respiratory tract).  Other methods, such 
as detecting M. tuberculosis nucleic acids in cultures (e.g. sputum or serum), are also 
employed (Wang et al., 2013).  Treatments include a combination of antibiotics, such as 
isoniazid, rifampicin, ethambutol, and pyrazinamide, which are to be taken for six to twelve 
months (WHO, 2014).  Directly Observed Therapy (DOT) is often used to ensure that 
patients take their medication properly (CDC, 2012).  This involves health care professionals 
watching patients take their medication and documenting the treatment process (CDC, 2012).  
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The global fight against tuberculosis has been impeded by the development of drug 
resistant strains of the disease (Fauci, 2008).  Multi-drug resistant tuberculosis (MDR-TB) is 
resistant to isoniazid and rifampicin, which are considered the two most common and 
powerful anti-tuberculosis drugs (WHO, 2014).  Extensively drug-resistant tuberculosis 
(XDR-TB) is a subtype of MDR-TB that is also resistant to at least one fluoroquinolone and 
a second-line injectable drug, such as amikacin or kanamycin (Jain and Dixit, 2008).  Drug 
resistance may evolve from infected individuals receiving erroneous concentrations of drugs 
or not finishing the prescribed treatment (Jain and Dixit, 2008).  Different combinations of 
the aforementioned antibiotics are prescribed in order to combat the development of drug 
resistance (WHO, 2014).  
II. Biotechnologies 
Currently, there is a wide array of tuberculosis diagnostics ranging from sputum 
smear microscopy to rapid assays that rely on the detection of M. tuberculosis bacterium, 
nucleic acids, or induced immune responses (Wang et al., 2013).  Some of these diagnostics 
have more potential to be developed into successful point of care tests.  For instance, the 
urine antigen detection test has less potential than the nucleic acid amplification test due to 
its lower sensitivity (Wang et al., 2013).  Sensitive and specific technology is defined as 
technology that yields minimal false positives and false negatives, respectively (Yager et al., 
2008).  The enzyme-linked immunosorbent assay (ELISA) also does not have much potential 
to be developed into a point of care diagnostic.  This assay quantifies the host’s immune 
response to the bacterium by measuring T cell release of interferon gamma after the T cells 
are mixed with antigens (Wang et al., 2013).  However, the ELISA does not have better 
sensitivity than a basic Mantoux skin test, which uses tuberculin, a protein derivative, to 
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detect an immune response (Wang et al., 2013).  Both of these tests require trained personnel 
to be administered, take 24 hours (ELISA) and 48 hours (Mantoux) to be read, and often 
yield false positive or negative results (Wang et al., 2013).  
 Biomarkers are physiological substances or processes that can be accurately measured 
in order to monitor diseases and the efficacy of treatments (Strimbu and Tavel, 2010).  
Examples of biomarkers include the biochemical analysis of blood and tissues (Strimbu and 
Tavel, 2010).  There is a lack of reliable biomarkers for tuberculosis because further research 
is needed in understanding how the bacterium interacts with its host (Wang et al., 2013).  A 
urine antigen detection test relies on biomarkers to analyze and detect tuberculosis antigens 
in the urine.  These antigens include lipoarabinomannan, which is a component of the M. 
tuberculosis cell wall.  Urine is an easy sample to collect in low resource settings, however, it 
yields low sensitivity in confirming infection.  It has been proposed that the combination of 
this assay and sputum smear microscopy can improve sensitivity (Wang et al., 2013). 
Nucleic acid amplification tests (NAAT) are commonly used to diagnose 
tuberculosis, detect drug resistance, and monitor treatments (Wang et al., 2013).  There are 
several methods that can be used to amplify nucleic acids, including loop-mediated 
isothermal amplification, multiplex ligation-dependent probe amplification, and microarrays 
(Wu and Tang, 2009).  Loop-mediated isothermal amplification (LAMP) relies on several 
primers in order to detect various regions on one gene of interest (Wu and Tang, 2009).  
LAMP allows for simultaneous nucleic acid amplification and gene recognition by 
combining and incubating samples, primers, DNA polymerase, and substrates at a constant 
temperature (Wu and Tang, 2009).  Multiplex ligation-dependent probe amplification 
(MLPA), relies on probes, each composed of oligonucleotides (Wu and Tang, 2009).  These 
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oligonucleotides work in pairs, with one containing a primer-binding site, 3’ recognition 
sequence, and a 5’ fluorescent label, and the other containing a specified length of DNA, 3’ 
reverse primer-binding site, and a 5’ recognition sequence (Wu and Tang, 2009).  The probes 
use these oligonucleotide pairs to anneal to the gene sequences of interest, after which the 
probes are ligated, in order to be amplified and detected by the polymerase chain reaction 
(PCR) and electrophoresis, respectively (Wu and Tang, 2009).  Microarrays also rely on 
oligonucleotides of specified lengths and PCR amplification in order to detect and identify 
DNA sequences (Wu and Tang, 2009).   
 Furthermore, microfluidic technologies are used to efficiently obtain measurements 
from small sample volumes (Yager et al., 2006).  The draw of microfluidics stems from the 
fact that they can perform complex functions on a miniaturized scale, and have the potential 
to be integrated into diagnostic tools that can function outside of laboratories, and without 
refrigeration or electricity (Yager et al., 2006).  Currently, microfluidics are most commonly 
incorporated into blood chemistry analysis, immunoassays, nucleic acid amplification tests, 
and flow cytometry (Yager et al., 2006).  Blood chemistry analysis involves approximately 
twelve to twenty tests being run on automated analyzers, designed to monitor physiological 
functions (Yager et al., 2006).  Immunoassays, commonly used as lateral flow strip assays, 
detect proteins with labeled antibodies in numerous samples, including blood, serum, and 
urine (Yager et al., 2006).  Flow cytometry is used to count cells with specific physical and 
chemical compositions (Yager et al., 2006). 
 The evolution of nanotechnology and microfluidics has lead to the development of M. 
tuberculosis biosensors (Wang et al., 2013).  Essentially, these biosensors work in 
conjunction with an analyzer device by responding to physiological and chemical changes in 
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a specific area (Wang et al., 2013).  Biosensors contain bioreceptors that detect specific 
analytes or molecules, thus enhancing the specificity of the biosensor (Wu and Tang, 2009).  
The detected analytes are then transduced into electrical signals that can be detected by 
electrochemical and optical platforms (Wu and Tang, 2009).  There are different types of 
biosensors that are based on antibody-antigen interactions, the bacterium itself, or nucleic 
acids obtained from the bacterium (Wang et al., 2013).  For instance, an optical biosensor 
may work by exciting samples with a laser light, and then passing a beam of monochromatic 
light through the sample in order to spectrographically detect M. tuberculosis strains (Wang 
et al., 2013).  Although biosensors tend to have high specificity, they are expensive and rely 
on complex and not readily accessibly equipment, such as lasers and fluorescence 
microscopes (Wang et al., 2013).  
An additional advance in the diagnostics field is multiplexed technology.  An ideal 
point of care device would rely on multiplexed techniques due to their efficiency and 
accuracy (Zumla et al., 2014).  These techniques have the ability to assay multiple substances 
(e.g. pathogens) simultaneously.  This generates more results at a faster rate, such as the 
concurrent detection of M. tuberculosis nucleic acids and drug resistant strains of the bacteria 
(Zumla et al., 2014).  One example of a multiplexed technique is a PCR test that relies on 
numerous primers within one PCR mixture in order to amplify and identify multiple nucleic 
acid fragments from different diseases at the same time (Zumla et al., 2014).  In the case of 
MLPA, multiplexing is conducted by altering the specified lengths of DNA in the 
oligonucleotides in different probe pairs (Wu and Tang, 2009).  This may especially be 
beneficial in diagnosing individuals who are infected with multiple diseases, such as in the 
case of tuberculosis and HIV co-infection. 
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III. Existing Tuberculosis Diagnostics 
In 2010, WHO endorsed the assay, Xpert MTB/RIF, created by Cepheid Inc. in 
Sunnyvale, California (Denkinger and Pai, 2012).  This endorsement subsequently lead to an 
increased interest in tuberculosis diagnostic development in the research community.  Xpert 
MTB/RIF is a cartridge-based nucleic acid amplification test that detects M. tuberculosis and 
rifampicin resistance from the sputum (Wang et al., 2013).   
This device essentially works by using five probes, each of which is a fragment of 
DNA oligonucleotides and complimentary to the rifampicin resistance domain of the M. 
tuberculosis rpoB gene (Van Rie et al., 2010).  Sputum is extracted from infected individuals 
and treated for fifteen minutes with a reagent containing sodium hydroxide and isopropanol 
(Van Rie et al., 2010).  The nucleic acids in the sputum are amplified by PCR, which causes 
the probes to undergo a conformational change that can be detected by fluorescence (Wang et 
al., 2013).  This fluorescence allows detection of bacterial DNA and mutations in the DNA 
that lead to drug resistance (Wang et al., 2013).    
Although PCR amplification techniques have been available and widely used in the 
diagnosis of tuberculosis, Xpert MTB/RIF integrated sample processing, DNA extraction, 
and PCR amplification in a disposable cartridge (Wang et al., 2013). This was a significant 
development because it greatly increased the specificity and sensitivity of the test (Wang et 
al., 2013).  However, Xpert MTB/RIF is not efficient in low resource settings due to its cost 
(<ten dollars per cartridge), maintenance requirements, and reliance on electricity (Niemz et 
al., 2011).  
Another example of an existing technology is the Biological System for Molecular 
Antibiotic Resistance Testing (B-SMART).  B-SMART is also a NAAT, and relies on 
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bacteriophages to detect the metabolic activity of bacteria that have been exposed to 
antibiotics (Sequella Incorporated, 2014).  These bacteriophages normally synthesize a 
nucleic acid, however, this synthesis is impaired when the phages are exposed to effective 
antibiotics (Sequella Incorporated, 2014).  Consequently, the nucleic acid serves as a 
biomarker for the detection of bacteria and drug resistance.  If the bacteria are resistant to the 
antibiotic, the antibiotic will have no effect on the bacteria’s metabolism, and the nucleic acid 
will be synthesized normally.  If the bacteria are not resistant to the antibiotic, the antibiotic 
will impair the bacteria’s metabolism, and subsequently, the synthesis of the nucleic acid.  
Ultimately, B-SMART assesses how well bacteria respond to the presence or absence of 
various antibiotics by amplifying nucleic acids (Sequella Incorporated, 2014).   
IV. Needs Assessment  
Various organizations, such as the Foundation for Innovative Diagnostics (FIND) and 
World Health Organization (WHO), are devoted to combatting prevailing illnesses, such as 
tuberculosis, by focusing on needs assessment and diagnostic solutions at the point of care.  
This is achieved by surveying patients’ needs in afflicted countries, building partnerships 
with other organizations, including government agencies and industries, and developing 
technologies.  A point of care diagnostic is defined as a test that is accurate, sensitive, 
specific, and inexpensive, does not require sophisticated equipment or highly trained 
personnel to operate, and can be read immediately and used at the community level 
(Denkinger and Pai, 2012).  
According to the WHO, tuberculosis can be diagnosed at four levels: community 
health clinics, microscopy centers, referral laboratories, and national reference laboratories 
(WHO, 2006).  Approximately 60% and 25% of patients are seen at the community health 
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clinics and microscopy centers, respectively (WHO, 2006).  Approximately 10% of patients 
are seen at the referral laboratories, where the primary testing methods are culture assays 
(WHO, 2006).  At the microscopy centers, the primary testing method involves observing 
sputum samples under a microscope, otherwise known as sputum smear microscopy.  This 
method is usually combined with a Ziehl-Neelsen stain, and is inexpensive and fast (Wang et 
al., 2013).  However, sputum smear microscopy requires trained personnel to detect the 
bacteria, which can only be detected at approximately 10,000 colony forming units per 
milliliter (Hobby et al., 1973).  This makes it difficult to detect the disease in its early stages, 
when there is less bacteria present in sputum (Wang et al., 2013).  Furthermore, sputum 
smear microscopy has low sensitivity (Denkinger and Pai, 2012).  These factors are 
particularly problematic in low-resource settings, where there is a shortage of trained lab 
technicians who can use sputum smear microscopy to accurately diagnose tuberculosis.  At 
the community health clinics, there is currently no diagnostic test, and patients are screened 
based on their presenting symptoms (WHO, 2006).  This means that the majority (60%) of 
patients do not have access to diagnostic tests at the point of care (WHO, 2006). 
There is no contention about the fact that a point of care device is necessary at the 
community level in order to combat the global health burden of tuberculosis.  There has been 
progress in the development of efficient, rapid, and sensitive technologies that can operate in 
the laboratory, such as Cepheid’s Gene Xpert MTB/RIF.  However, the reliance on a lab 
greatly minimizes public access to these technologies in impoverished areas (McNerney and 
Daley, 2011).  Several factors are responsible for the lack of an accurate, easy-to-use 
diagnostic that can provide results within the same day the individual is tested (McNerney 
and Daley, 2011).  These factors include underdeveloped medical infrastructure, limited 
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access to public health services, the difficulty of obtaining and working with sputum, and the 
high cost of technology.  Accurately diagnosing tuberculosis has substantial benefits.  This 
includes the patient receiving appropriate treatment before spreading the disease to others, 
health care providers preventing the disease from progressing, and public health 
organizations having up to date information for more efficient public policy development 
(Mahony, 2010).  Additionally, timely diagnosis of the disease may prevent drug resistant 
strains from evolving (McNerney and Daley, 2011).   
Current diagnostics have poor detection rates and may take weeks to provide results.  
M. tuberculosis is a big challenge to work with because it grows slowly, taking 
approximately 4-8 weeks to grow on solid culture and 10-14 days to grow in liquid cultures 
(Wang et al., 2013).  Also, the bacterium’s tendency to lay dormant in granulomas leads to 
infected individuals not seeking treatment in a timely manner.  This is not only detrimental to 
the individual’s health, but also increases the risk of the disease spreading to others.  
Moreover, sputum is hard to work with.  In order to obtain accurate and consistent results, 
sputum must be properly collected, stored, and transported, which may be difficult in low 
resource setting (e.g. where there may be no electricity) (Wang et al., 2013).  Sputum is also 
hard to collect from immunocompromised individuals, such as children and those co-infected 
with HIV (Leonard et al., 2005).  Children account for 6-10% of tuberculosis cases 
worldwide and 40% of cases in countries with a high burden of tuberculosis (e.g. Central 
Africa and Southeast Asia) (CDC, 2014).  Approximately 33% of individuals that are HIV-
infected develop latent tuberculosis (WHO, 2014).  Sputum from these individuals is 
compromised because not only can a limited amount be collected, but it is also usually mixed 
with blood, which could lead to inaccuracies in the results by inhibiting PCR (Abu Al-Soud 
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and Rådström, 2000).  Studies have also show that up to three sputum specimens should be 
collected in order to obtain a sensitive and accurate diagnosis (Leonard et al., 2005).  
Ultimately, problems with diagnosing tuberculosis at the point of care arise from three 
limitations: low specificity of the diagnostic, unavailability of appropriate diagnostic 
technology in developing countries, and the inability to observe and treat infected individuals 
for the entire course of treatment (Wang et al., 2013). There is an urgent need for an easy-to-
use, inexpensive, portable, and fast diagnostic device for tuberculosis that can be used at the 
point of care and relies on sample types other than sputum (Wang et al., 2013).  
V. The NIH and Predicted Research Outcomes  
The National Institutes of Health (NIH), an agency of the United States Department 
of Health and Human Services, is composed of twenty-seven institutes and centers with 
specific research foci (NIH, 2014).  For instance, the National Heart, Lung, and Blood 
Institute and National Institute of Allergy and Infectious Diseases are considered to be two of 
the twenty-seven institutes comprising the NIH, and fund many of the tuberculosis diagnostic 
projects (NIH, 2014).  Most of these institutes and centers receive funding from Congress, 
and then they allocate these funds to biomedical and health-related research (NIH, 2014).  
The NIH offers several research grants, including the NIH Research Project Grant Program 
and Small Business Innovative Research grant (NIH, 2014).  The NIH Research Project 
Grant Program, for instance, is usually awarded for three to five years and has no dollar limit 
(NIH, 2014).  The amount of funding allocated to research is correlated with various 
measures of the burden of disease, including measures that take into account age of infected 
individuals, mortality rates, and the extent of disability (Gross et al., 1999).  However, the 
NIH has been criticized for not taking into account other measures, such as disease 
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prevalence (total number of cases at a given time) and incidence (number of new cases at a 
given time), when allocating funds (Gross et al., 1999). 
 The National Institutes of Health Research Portfolio Online Reporting Tools 
Expenditures and Results (NIH RePORTer) publicly reports information about publications 
and projects funded by the NIH.  Examining the projects undertaken by both academic and 
industrial sectors may reveal whether or not the development of a point of care tuberculosis 
diagnostic is feasible and if so, what underlying factors, besides technological issues, are 
delaying its development.  In 2012, UNITAID, a global health organization devoted to 
making health care products more accessible and affordable for developing countries, 
released the “TB Diagnostic Landscape Report”.  The report outlined existing tuberculosis 
diagnostics and addressed what the diagnostics market was lacking (UNITAID, 2012).  
Consequently, this report, in addition to WHO’s endorsement of Xpert MTB/RIF, generated 
an increased interest in the field of point of care diagnostics, specifically tuberculosis.  This 
leads the investigators of this project to hypothesize that there will be more tuberculosis point 
of care diagnostic projects in 2014 than in 2008.  Due to the challenges of working with 
sputum, another hypothesized difference between 2008 and 2014 projects is that more 
diagnostics will rely on other sample types. 
Methods 
This investigation sought out to compare data from diagnostic development projects 
from 2008, 2011, and 2014.  This study is an extension of previous research conducted by 
Dr. Steven Casper at Keck Graduate Institute in Claremont, California.  Dr. Casper had 
already obtained data from 2011, and his research methods served as a reference for 
acquiring data from 2008 and 2014.  Initially, data sets from each year were planned on being 
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used in this analysis.  However, due to inconsistencies in data collection between the 
previously obtained 2011 data, and the 2008 and 2014 data specifically collected for this 
study, only the 2008 and 2014 data were used.  The NIH RePORTer was used to search for 
an extensive range of diagnostic development projects.  Search criteria included “point of 
care diagnostics”, “ multiplex diagnostics”, “tuberculosis point of care”, and “device 
development”.  Additionally, there was a search tool to view similar projects, so when one 
device development project was found, others were searched for using this option. 
The goal was to find all of the diagnostic projects being funded by the NIH.  These 
projects were not limited to tuberculosis device development, and included all point of care 
device development.  Projects were searched for until the data were saturated, meaning there 
were no more point of care diagnostic development projects or the remaining projects were 
repeats of the same project receiving a different type of grant.  The data were then 
categorized by which company or university was responsible for the project, the amount of 
money being funded to the project, the type of NIH grant awarded, whether or not the device 
being developed was multiplex, the type of technology being developed and its purpose, how 
much the proposed device would cost (cost aim), the sensitivity of the device, the amount of 
time the device would take to provide results, the size of the device, the power of the device, 
the sample type that could be tested, whether or not tuberculosis was the primary market, 
whether or not a device was being developed (e.g. rather than a kit), and the markets the 
device would serve.  The principle investigators (PIs) of the project were considered when 
classifying projects as part of the industrial or academic sector. 
This information was gathered primarily from the “details” and “descriptions” 
subsections on the NIH RePORTer’s project pages.  More information on the projects, such 
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as other collaborators, or the size and sensitivity of the device, was gathered by researching 
the device further outside of the NIH RePORTer.  The data gathered were then analyzed by 
calculating the total, average, and median funding of tuberculosis, non-tuberculosis, and all 
projects in 2008 and 2014.  The various markets for the device developments were totaled 
and compared by generating a bar graph.  The sample types were also compared by 
generating pie charts.  
Results 
All of the diagnostic development projects in 2008 (n=61) and 2014 (n=68) were researched on the NIH RePORTer.  These project
catered to approximately twenty-seven and twenty
For both years, tuberculosis was the leading market, followed by HIV/AIDS in 2014 (Figure 2), and influenza and other respira
viruses in 2008 (Figure 1). 
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In 2008, there were ten industrial and four academic tuberculosis diagnostic development projects funded by the NIH. The 
technologies being developed and sample types varied, however, all of the projects were multiplex (Tablea 1-2). 
 
Table 1. Tuberculosis diagnostic projects in the industrial sector in 2008. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Company Funding 
(USD) 
Technology Sample Multiplex 
Howard Shapirio 
Lab 
299,229 
 
Flow cytometry 
assay 
Sputum Yes 
Investigen, Inc. 293,209 
 
NAAT  Sputum 
 
Yes 
Lynntech, Inc. 145,242 
 
NAAT Sputum 
 
Yes 
Biosense 
Technologies, Inc. 
100,000 
 
Blood-based 
assay 
Blood 
 
Yes 
Chembio 
Diagnostic 
Systems, Inc. 
296,406 
 
Blood-based 
assay 
Blood 
 
Yes 
Pulsar Clinical 
Technologies, Inc 
120,209 
 
Immunoassay 
 
Serum 
 
 
Yes 
Sequella, Inc 244,346 
 
NAAT Sputum 
 
Yes 
Investigen, Inc. 130,141 
 
NAAT 
 
Sputum 
 
Yes 
Cepheid Inc.  1,160,774 
 
NAAT Sputum Yes 
Akonni 
Biosystems, Inc. 
296,316 
 
Immunoassay 
 
Nasal swabs, 
Sputum 
 
Yes 
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Table 2.  Tuberculosis diagnostic development projects in the academic sector in 2008. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
University Funding 
(USD) 
Technology Sample Multiplex 
UCSF 122,288 
 
NAAT 
 
Sputum Yes 
UCD 84,450 
 
Immunoassay Serum Yes 
University of Cape Town 132,435 
 
Microscope 
development 
Sputum Yes 
Beth Israel Deaconess Medical 
Center w/ Harvard Medical 
School of Public Health 
126,630 
 
Antigen detection test 
 
Urine 
 
Yes 
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In 2014, there were seven industrial and ten academic tuberculosis diagnostic development projects funded by the NIH.  Similarly to 
2008, the technologies being developed and sample types varied, however, all of the projects were multiplex (Tables 3-4).   
 
Table 3.  Tuberculosis diagnostic development projects in the industrial sector in 2014. 
 
 
  
Company Funding (USD)  Technology Sample Multiplex 
Akonni Biosystems 399,604 
 
NAAT 
 
Sputum 
 
Yes 
Wave 80 Biosciences, Inc. 207,164 
 
Microfluidic bioassay Sputum 
 
Yes 
Akonni Biosystems 1,364,708 
 
NAAT 
 
Sputum 
 
Yes 
Sequella, Inc. 231,000 
 
NAAT 
 
Sputum 
 
Yes 
ImmunoMycologies, Inc. 299,640 
 
Immunoassay 
 
Serum, Urine 
 
Yes 
TB Biosciences, Inc. 515,802 
 
Immunoassay Serum 
 
Yes 
Viti, Inc. 996,814 
 
Blood-based assay Blood 
 
Yes 
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   Table 4.  Tuberculosis diagnostic development projects in the academic sector in 2014. 
University Funding (USD) Technology Sample Multiplex 
Harvard Medical 
School 
2,916,905 NAAT Sputum, Urine Yes 
Keck Graduate Institute 
of Applied Life 
Sciences 
607, 711 
 
NAAT Sputum 
 
Yes 
RBHS New Jersey 
Medical School 
749,849 
 
Flow cytometry assay Blood 
 
Yes 
UCSF 1,167,864 
 
Biomarker assay  Blood 
 
Yes 
Albert Einstein College 
of Medicine 
208,750 
 
Biomarker assay Serum 
 
Yes 
RBHS New Jersey 
Medical School 
1,123,270 
 
Blood based assay Blood 
 
Yes 
Stellenbosch University 
Tygerberg Campus 
132, 468 
 
NAAT Sputum 
 
Yes 
RBHS New Jersey 
Medical School 
1,548,810 
 
NAAT Sputum 
 
Yes 
University of 
Pennsylvania 
186,767 
 
Biosensor Sputum 
 
Yes 
Michigan State 
Universty 
202,234 
 
Biomarker assay Sputum 
 
Yes 
In both 2008 and 2014, the majority of the tuberculosis 
was an increase in the use of serum and blood as sample types (Figure 4).
                                                    Figure 3.  Sample types used by proposed 2008 
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diagnostics relied on sputum samples (Figures 3-4).  However, in 2014, there 
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A comparison was conducted between all diagnostic development projects, including tuberculosis, and just the tuberculosis diagnostic 
development projects being funded by the NIH.  The comparison revealed that in 2008, approximately 15% of the total funds were 
allocated to tuberculosis diagnostics projects whereas in 2014, approximately 39% of the total funds were allocated to tuberculosis 
diagnostics projects (Table 5-6).  In 2014, there were fewer projects in the industrial sector than in 2008, however, more funding was 
allocated to the industrial sector in 2014 (Tables 5-6).  Even though there were only three more tuberculosis diagnostic projects in 
2014 than in 2008, 8,567,506 USD more was allocated to projects in 2014 (Tables 5-6).       
        
   Table 5.  Diagnostic development funding by the NIH in 2008. 
 
 
 
 
 
 
 
 All Diagnostic Development   
(USD) 
Tuberculosis Diagnostic Development  
(USD) 
Total Funding 
 
23,733,784 3,551,675 
Median Funding 
 
299,978 138,839 
 
Average Funding 
 
387,280 253,691 
Academic Grants 
 
10,935,577 465,803 
Industrial Grants 12,798,207 3,085,872 
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       Table 6.  Diagnostic development funding by the NIH in 2014. 
 
 
 All Diagnostic Development  
(USD) 
Tuberculosis Diagnostic Development 
(USD) 
Total Funding 
 
31,417,193 
 
12,119,181 
 
Median Funding 
 
329,390 
 
515,802 
 
Average Funding 
 
541,676 
 
807,945 
 
Academic Grants 
 
15,058,463 
 
8,104,449 
 
Industrial Grants 16,358,730 
 
4,014,732 
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Discussion 
 
Thorough research has been conducted in the field of tuberculosis treatment, and the 
disease has proven to be highly treatable and curable (Fox et al., 1999).  However, the 
problem of diagnosing the disease rapidly and effectively in low-resource settings, where 
unfortunately, tuberculosis is most prevalent, has yet to be resolved (WHO, 2014).  A 
considerable amount of attention has been directed at developing diagnostic technologies for 
tuberculosis.  In fact, in both 2008 and 2014, tuberculosis was the leading market for 
diagnostic development projects (Figures 1-2).  
The review of proposed technologies revealed that a wide range of technology types 
was funded, that all technologies were multiplexed, a progression to the use of more serum 
and blood sample types in 2014 compared to 2008, and that there were more academic 
projects in 2014 (Figures 3-4, Tables 1-4).  There was no notable difference between the 
technology types being developed in 2008 and 2014 or between academic and industrial 
sectors (Tables 1-4).  It is interesing, yet not surprising, that all of the technologies are 
multiplexed, since multiplexed technology is more efficient and accurate (Zumla et al., 
2014).  It is also economically savvy to develop multiplex technology because it can cater to 
numerous diagnostic markets.  For example, if a point of care multiplex device does not 
generate a signigicant profit from the tuberculosis market in developing countries, it may 
generate a profit by being incorporated into a different market in developed countries.  The 
use of more serum and blood samples supports the initial hypothesis that sputum would be 
relied on less as more point of care diagnostics are developed.  Sputum is not only difficult to 
extract, but the necessity of obtaining, storing, and transporting more than one specimen to 
laboratories without having effective medical record systems in place, makes an accurate and 
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timely tuberculosis diagnosis almost impossible in developing countries (Wilson et al., 
2011).  The development of a device that can effectively operate independent of those 
variables can bypass the complicated logistical problems of health-care systems (Wilson et 
al., 2011).  
 In 2008, approximately 16% and 27% of the total academic and industrial grants, 
respectively, were given to tuberculosis projects.  In 2014, approximately 32% and 19% of 
the total academic and industrial grants, respectively, were given to tuberculosis projects 
(Tables 1-6).  It is important to note, however, that this investigation was able to find seven 
more NIH-funded projects in 2014 than in 2008.  Most of the tuberculosis projects being 
funded by the NIH in 2008 were focused on researching the pathogenesis of the disease.  
Additionally, more of the total NIH funds were granted to tuberculosis-related projects in 
2014 compared to 2008 (39% in 2014 compared to 15% in 2008) (Tables 5-6). These 
findings are in alignment with the hypothesis that there would be a larger focus on point of 
care devices in 2014 due to the WHO endorsement of Xpert MTB/RIF in 2010 and 
UNITAID’s 2012 report.  The endorsement and the report instigated the resurgence of 
interest in the tuberculosis diagnostic development, which explains why there were more 
projects in 2014 (Wang et al., 2013).  
If point of care diagnostics are to be successfully implemented in developing 
countries, industrial and academic sectors need to take into consideration the constraints 
imposed by low-resource settings.  First, developing countries have fewer well-funded 
centralized testing centers compared to developed countries.  Centralized testing centers 
employ highly trained personnel, and have sophisticated infrastructure and resources (Chin et 
al., 2007).  However, the centralized testing centers in developing countries lack in resources 
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compared to centers in developed countries (Chin et al., 2007).  Centralized testing centers 
can have moderate to high priced (e.g. more than 10,000 USD) technology if the price of 
disposables, such as the Xpert MTB/RIF cartridges is kept to a minimum (e.g. pennies) (Chin 
et al., 2007).  This is a major criticism of Xpert MTB/RIF because currently the cartridges do 
not meet this cost requirement.  In contrast, point of care diagnostics requires minimal costs 
of both technology and disposables (Chin et al., 2007).  These economic and technological 
constraints severely hinder the development of an ideal point of care device, but they may 
also explain the greater interest in diagnostic development in the academic sector in 2014 
(Table 4).   
Research in the industrial sector is focused more on developing profitable 
technologies whereas research in the academic sector is focused more on solving scientific 
problems (Sauermann and Stephan, 2010).  Therefore, there may not be as many incentives 
for industries to focus on or fund projects that cannot generate a significant profit, such as the 
cheap point of care diagnostics needed in developing countries.  This would support why, in 
2014, there was more money granted to industrial projects compared to academic projects, 
even though there were three more academic than industrial projects.  The greater number of 
academic projects may stem from the incentive of finding a solution (potentially award-
winning) to the tuberculosis global health challenge.  The greater level of funding given to 
fewer industrial projects may stem from the economic and policy incentives of developing 
effective and profitable technologies for either centralized testing centers or health care 
systems in developed countries.  It is important to consider that private industries also fund 
approximately twice as many research projects as the NIH, which means that the NIH fund 
allocation only paints a small portion of the bigger picture (Gross et al., 1999).  More focus 
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on the point of care diagnostic dilemma in the academic sector may be beneficial due to the 
greater motivation towards finding an effective solution, rather than a marketable one.  
However, more research needs to be focused on finding a non-sputum based diagnostic. 
Inaccuracies in the obtained data may have stemmed from double counting projects 
and not finding all of the diagnostic development projects.  Double counting may have 
occurred because some industries will collaborate with academic sectors to work on projects, 
and consequently receive separate grants from the NIH.  For instance, in 2008, Cepheid 
Incorporated collaborated with the New Jersey Medical School to develop a NAAT cartridge 
(Table 1).  To avoid this problem, all of the projects were thoroughly researched outside of 
the NIH RePORTer, however, some projects had no publications describing them.  Most of 
the projects did not have information about the cost, size, sensitivity, time, or power supply 
of the proposed diagnostic.  This made it difficult to establish how successful these projects 
would be at the point of care in low-resource settings.  Future investigations should conduct a 
more thorough review of collaborations between academic and industrial sectors.  More 
years, in addition to 2008 and 2014, should be reviewed in order to establish if there has been 
a trend in diagnostic development in the past decade.    Furthermore, it would be interesting 
to examine what diagnostic projects in 2008 were finalized or successfully implemented in 
health care systems.   
Conclusion 
 
 In summation, progress has been made towards developing a tuberculosis diagnostic 
device that can function effectively at the point of care.  There are more diagnostics being 
developed and many of them are non-sputum based.  However, developing a tuberculosis 
diagnostic is a multi-faceted problem.  The high cost of technology and underdeveloped 
Tounkel 32 
 
medical infrastructure within low-resource settings are major factors that need to be 
addressed before a point of care device can be actualized.  For instance, it is much easier to 
implement diagnostics in healthcare systems that provide access to well-funded laboratories 
and highly trained lab technicians (Wilson et al., 2011).  Hopefully, the academic sector’s 
focus on diagnostic development will persist and result in an effective solution that can be 
implemented at the community level.  With more research come more solutions that can 
combat the global burden of tuberculosis. 
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